Protara Therapeutics Ownership 2024 | Who Owns Protara Therapeutics Now?
Institutional Ownership
91.32%
Insider Ownership
6.13%
Retail Ownership
2.55%
Institutional Holders
41.00
Protara Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | 20.18% | 1.21% | 2,304,262 | -388,332 | -14.42% | 5,299,803 | Jun 30, 2024 |
| RA CAPITAL MANAGEMENT, L.P. | 16.64% | 0.05% | 1,900,000 | 1,900,000 | 100.00% | 3,952,000 | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | 8.62% | 0.60% | 984,113 | 815,671 | 484.24% | 2,046,955 | Jun 30, 2024 |
| BOXER CAPITAL, LLC | 7.11% | 0.09% | 811,627 | 602,400 | 287.92% | 1,688,184 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 4.70% | 0.01% | 536,832 | 337,161 | 168.86% | 1,116,611 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 4.55% | 0.01% | 520,000 | 520,000 | 100.00% | 1,081,600 | Jun 30, 2024 |
| VELAN CAPITAL INVESTMENT MANAGEMENT LP | 4.20% | 0.57% | 480,000 | 480,000 | 100.00% | 998,400 | Jun 30, 2024 |
| VANGUARD GROUP INC | 3.74% | - | 427,612 | - | - | 889,433 | Jun 30, 2024 |
| CVI HOLDINGS, LLC | 2.65% | 0.54% | 302,746 | 302,746 | 100.00% | 629,712 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 1.58% | 0.07% | 180,712 | -21,989 | -10.85% | 375,881 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 1.36% | 0.00% | 155,773 | 136,025 | 688.80% | 324,008 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 1.32% | 0.00% | 150,400 | 65,800 | 77.78% | 312,832 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.23% | - | 140,526 | 57,619 | 69.50% | 292,327 | Jun 30, 2024 |
| OPPENHEIMER & CO INC | 1.11% | 0.00% | 127,181 | 117,181 | 1171.81% | 264,536 | Jun 30, 2024 |
| BLACKROCK INC. | 1.01% | - | 115,273 | 84,409 | 273.49% | 239,767 | Jun 30, 2024 |
| PRIVIUM FUND MANAGEMENT (UK) LTD | 1.00% | 0.09% | 114,708 | -5,022 | -4.19% | 232,857 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.88% | 0.00% | 100,001 | 100,001 | 100.00% | 208,002 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 0.68% | 0.00% | 77,351 | 77,351 | 100.00% | 160,890 | Jun 30, 2024 |
| LPL FINANCIAL LLC | 0.39% | - | 44,000 | 16,000 | 57.14% | 91,520 | Jun 30, 2024 |
| CIBC WORLD MARKET INC. | 0.32% | 0.00% | 37,000 | 37,000 | 100.00% | 77,000 | Jun 30, 2024 |
Protara Therapeutics's largest institutional shareholder is OPALEYE MANAGEMENT INC., holding 20.18% of the company's total share outstanding, currently valued at $5.30M. The top 10 institutional shareholders own together 73.97% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | 20.18% | 1.21% | 2,304,262 | -388,332 | -14.42% | 5,299,803 | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | 8.62% | 0.60% | 984,113 | 815,671 | 484.24% | 2,046,955 | Jun 30, 2024 |
| VELAN CAPITAL INVESTMENT MANAGEMENT LP | 4.20% | 0.57% | 480,000 | 480,000 | 100.00% | 998,400 | Jun 30, 2024 |
| CVI HOLDINGS, LLC | 2.65% | 0.54% | 302,746 | 302,746 | 100.00% | 629,712 | Jun 30, 2024 |
| PRIVIUM FUND MANAGEMENT (UK) LTD | 1.00% | 0.09% | 114,708 | -5,022 | -4.19% | 232,857 | Jun 30, 2024 |
| BOXER CAPITAL, LLC | 7.11% | 0.09% | 811,627 | 602,400 | 287.92% | 1,688,184 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 1.58% | 0.07% | 180,712 | -21,989 | -10.85% | 375,881 | Jun 30, 2024 |
| RA CAPITAL MANAGEMENT, L.P. | 16.64% | 0.05% | 1,900,000 | 1,900,000 | 100.00% | 3,952,000 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 4.70% | 0.01% | 536,832 | 337,161 | 168.86% | 1,116,611 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 4.55% | 0.01% | 520,000 | 520,000 | 100.00% | 1,081,600 | Jun 30, 2024 |
| OPPENHEIMER & CO INC | 1.11% | 0.00% | 127,181 | 117,181 | 1171.81% | 264,536 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.88% | 0.00% | 100,001 | 100,001 | 100.00% | 208,002 | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.21% | 0.00% | 24,200 | -34,800 | -58.98% | 50,336 | Jun 30, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.18% | 0.00% | 20,191 | -2,456 | -10.84% | 41,997 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 1.36% | 0.00% | 155,773 | 136,025 | 688.80% | 324,008 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 1.32% | 0.00% | 150,400 | 65,800 | 77.78% | 312,832 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 0.68% | 0.00% | 77,351 | 77,351 | 100.00% | 160,890 | Jun 30, 2024 |
| CIBC WORLD MARKET INC. | 0.32% | 0.00% | 37,000 | 37,000 | 100.00% | 77,000 | Jun 30, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.04% | 0.00% | 4,019 | 1,439 | 55.78% | 8,360 | Jun 30, 2024 |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.17% | 0.00% | 19,428 | 19,428 | 100.00% | 40,000 | Jun 30, 2024 |
The largest Protara Therapeutics shareholder by % of total assets is OPALEYE MANAGEMENT INC.. The company owns 2.30M shares of Protara Therapeutics (TARA), representing 1.21% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 16.64% | 0.05% | 1,900,000 | 1,900,000 | 100.00% | 3,952,000 | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | 8.62% | 0.60% | 984,113 | 815,671 | 484.24% | 2,046,955 | Jun 30, 2024 |
| BOXER CAPITAL, LLC | 7.11% | 0.09% | 811,627 | 602,400 | 287.92% | 1,688,184 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 4.55% | 0.01% | 520,000 | 520,000 | 100.00% | 1,081,600 | Jun 30, 2024 |
| VELAN CAPITAL INVESTMENT MANAGEMENT LP | 4.20% | 0.57% | 480,000 | 480,000 | 100.00% | 998,400 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 4.70% | 0.01% | 536,832 | 337,161 | 168.86% | 1,116,611 | Jun 30, 2024 |
| CVI HOLDINGS, LLC | 2.65% | 0.54% | 302,746 | 302,746 | 100.00% | 629,712 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 1.36% | 0.00% | 155,773 | 136,025 | 688.80% | 324,008 | Jun 30, 2024 |
| OPPENHEIMER & CO INC | 1.11% | 0.00% | 127,181 | 117,181 | 1171.81% | 264,536 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.88% | 0.00% | 100,001 | 100,001 | 100.00% | 208,002 | Jun 30, 2024 |
| BLACKROCK INC. | 1.01% | - | 115,273 | 84,409 | 273.49% | 239,767 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 0.68% | 0.00% | 77,351 | 77,351 | 100.00% | 160,890 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 1.32% | 0.00% | 150,400 | 65,800 | 77.78% | 312,832 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.23% | - | 140,526 | 57,619 | 69.50% | 292,327 | Jun 30, 2024 |
| CIBC WORLD MARKET INC. | 0.32% | 0.00% | 37,000 | 37,000 | 100.00% | 77,000 | Jun 30, 2024 |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.17% | 0.00% | 19,428 | 19,428 | 100.00% | 40,000 | Jun 30, 2024 |
| LPL FINANCIAL LLC | 0.39% | - | 44,000 | 16,000 | 57.14% | 91,520 | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.25% | - | 28,976 | 11,385 | 64.72% | 60,270,000 | Jun 30, 2024 |
| GROUP ONE TRADING, L.P. | 0.02% | - | 2,550 | 2,550 | 100.00% | 5,304,000 | Jun 30, 2024 |
| ROYAL BANK OF CANADA | 0.06% | - | 6,302 | 2,316 | 58.10% | 13,000 | Jun 30, 2024 |
As of Jun 30 2024, Protara Therapeutics's largest institutional buyer is RA CAPITAL MANAGEMENT, L.P.. The company purchased 1.90M stocks of TARA, valued at $3.95M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | 20.18% | 1.21% | 2,304,262 | -388,332 | -14.42% | 5,299,803 | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | - | - | - | -87,900 | -100.00% | - | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.21% | 0.00% | 24,200 | -34,800 | -58.98% | 50,336 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 1.58% | 0.07% | 180,712 | -21,989 | -10.85% | 375,881 | Jun 30, 2024 |
| SIMPLEX TRADING, LLC | - | - | - | -17,850 | -100.00% | - | Jun 30, 2024 |
| TWO SIGMA SECURITIES, LLC | - | - | - | -17,393 | -100.00% | - | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | - | - | - | -12,126 | -100.00% | - | Jun 30, 2024 |
| WOLVERINE TRADING, LLC | - | - | - | -10,700 | -100.00% | - | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | - | - | - | -6,314 | -100.00% | - | Jun 30, 2024 |
| PRIVIUM FUND MANAGEMENT (UK) LTD | 1.00% | 0.09% | 114,708 | -5,022 | -4.19% | 232,857 | Jun 30, 2024 |
| WOLVERINE TRADING, LLC | 0.10% | - | 11,200 | -4,800 | -30.00% | 23,296 | Jun 30, 2024 |
| UBS GROUP AG | - | - | - | -3,725 | -100.00% | - | Jun 30, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.18% | 0.00% | 20,191 | -2,456 | -10.84% | 41,997 | Jun 30, 2024 |
| ADAR1 CAPITAL MANAGEMENT, LLC | - | - | - | -2,000 | -100.00% | - | Jun 30, 2024 |
| WELLS FARGO & COMPANY/MN | 0.00% | - | 500 | -70 | -12.28% | 1,040 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | - | - | - | -22 | -100.00% | - | Jun 30, 2024 |
| VANGUARD GROUP INC | 3.74% | - | 427,612 | - | - | 889,433 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.16% | - | 17,907 | - | - | 37,246 | Jun 30, 2024 |
| STATE STREET CORP | 0.23% | - | 26,600 | - | - | 55,328,000 | Jun 30, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 100 | - | - | 208 | Jun 30, 2024 |
As of Jun 30 2024, Protara Therapeutics's biggest institutional seller is OPALEYE MANAGEMENT INC.. The company sold -0.39M shares of TARA, valued at $5.30M.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 16.64% | 0.05% | 1,900,000 | 1,900,000 | 100.00% | 3,952,000 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 4.55% | 0.01% | 520,000 | 520,000 | 100.00% | 1,081,600 | Jun 30, 2024 |
| VELAN CAPITAL INVESTMENT MANAGEMENT LP | 4.20% | 0.57% | 480,000 | 480,000 | 100.00% | 998,400 | Jun 30, 2024 |
| CVI HOLDINGS, LLC | 2.65% | 0.54% | 302,746 | 302,746 | 100.00% | 629,712 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.88% | 0.00% | 100,001 | 100,001 | 100.00% | 208,002 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 0.68% | 0.00% | 77,351 | 77,351 | 100.00% | 160,890 | Jun 30, 2024 |
| CIBC WORLD MARKET INC. | 0.32% | 0.00% | 37,000 | 37,000 | 100.00% | 77,000 | Jun 30, 2024 |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.17% | 0.00% | 19,428 | 19,428 | 100.00% | 40,000 | Jun 30, 2024 |
| GROUP ONE TRADING, L.P. | 0.02% | - | 2,550 | 2,550 | 100.00% | 5,304,000 | Jun 30, 2024 |
Protara Therapeutics's largest new institutional shareholder by number of shares is RA CAPITAL MANAGEMENT, L.P., purchased 1.90M shares, valued at $3.95M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| STEMPOINT CAPITAL LP | - | - | - | -87,900 | -100.00% | - | Jun 30, 2024 |
| SIMPLEX TRADING, LLC | - | - | - | -17,850 | -100.00% | - | Jun 30, 2024 |
| TWO SIGMA SECURITIES, LLC | - | - | - | -17,393 | -100.00% | - | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | - | - | - | -12,126 | -100.00% | - | Jun 30, 2024 |
| WOLVERINE TRADING, LLC | - | - | - | -10,700 | -100.00% | - | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | - | - | - | -6,314 | -100.00% | - | Jun 30, 2024 |
| UBS GROUP AG | - | - | - | -3,725 | -100.00% | - | Jun 30, 2024 |
| ADAR1 CAPITAL MANAGEMENT, LLC | - | - | - | -2,000 | -100.00% | - | Jun 30, 2024 |
| JPMORGAN CHASE & CO | - | - | - | -22 | -100.00% | - | Jun 30, 2024 |
Protara Therapeutics's largest sold out institutional shareholder by shares sold is STEMPOINT CAPITAL LP, sold -87.90K shares, valued at -, as of undefined.
Protara Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| BRIDGEWAY FUNDS INC | 0.02% | 59,000 | -5,000 | -7.81% | Mar 28, 2024 |
| FRANKLIN STRATEGIC SERIES | 0.02% | 145,500 | - | - | Jan 31, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.00% | 669 | - | - | Mar 31, 2024 |
| ALPS ETF Trust | 0.00% | 19,475 | - | - | Feb 29, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 424,969 | -140,668 | -24.87% | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.00% | 592 | - | - | Mar 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.00% | 5,857 | - | - | Mar 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 72,568 | -351 | -0.48% | Feb 29, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 7,847 | - | - | Mar 31, 2024 |
| OLD WESTBURY FUNDS INC | 0.00% | 26,596 | - | - | Jan 31, 2024 |
| ARTISAN PARTNERS FUNDS INC | 0.00% | 264,464 | - | - | Mar 31, 2024 |
| GPS Funds I | 0.00% | 827 | - | - | Mar 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 335 | - | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 3,990 | - | - | Feb 29, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 178 | - | - | Mar 31, 2024 |
| RUSSELL INVESTMENT CO | 0.00% | 9,999 | - | - | Jan 31, 2024 |
| SunAmerica Specialty Series | 0.00% | 17 | - | - | Apr 30, 2021 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 4,100 | - | - | Jan 31, 2024 |
| PGIM ETF TRUST | 0.00% | 1,762 | - | - | Feb 29, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 4,714 | - | - | Feb 29, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 9,212 | - | - | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 2,076 | - | - | Mar 28, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 13,940 | - | - | Mar 31, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 700 | - | - | Mar 31, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 7,597 | - | - | Jan 31, 2024 |
| ProFunds | 0.00% | 84 | - | - | Mar 31, 2024 |
| VALIC Co I | 0.00% | 1,836 | - | - | Feb 29, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 25,379 | - | - | Mar 31, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 12,238 | - | - | Feb 29, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 946 | - | - | Jan 31, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 931 | - | - | Jan 31, 2024 |
| Blackstone Alternative Investment Funds | 0.00% | 400 | - | - | Mar 31, 2024 |
| ALLSPRING MASTER TRUST | 0.00% | 203 | - | - | Feb 29, 2024 |
| Invesco Exchange-Traded Self-Indexed Fund Trust | 0.00% | 659 | - | - | Feb 29, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 377 | - | - | Mar 31, 2024 |
| TIAA-CREF FUNDS | 0.00% | 8,040 | - | - | Mar 31, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 35 | - | - | Feb 29, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 145 | - | - | Feb 29, 2024 |
| iSHARES TRUST | 0.00% | 21,013 | -1,358 | -6.07% | Mar 31, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 418 | - | - | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 1,254 | -496 | -28.34% | Mar 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 482 | - | - | Dec 31, 2023 |
| John Hancock Funds II | 0.00% | 6,599 | - | - | Feb 29, 2024 |
| Bridge Builder Trust | 0.00% | 1,682 | - | - | Mar 31, 2024 |
| PACIFIC SELECT FUND | 0.00% | 979 | - | - | Mar 31, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 500 | - | - | Mar 31, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 372 | - | - | Mar 31, 2024 |
| PRINCIPAL FUNDS, INC. | 0.00% | 793 | - | - | Feb 29, 2024 |
Protara Therapeutics's largest mutual fund holder by % of total assets is "BRIDGEWAY FUNDS INC", owning 59.00K shares, compromising 0.02% of its total assets.
Protara Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 41 | 5.13% |
| 31 Mar, 24 | 39 | 21.88% |
| 31 Dec, 23 | 32 | - |
| 30 Sep, 23 | 32 | 6.67% |
| 30 Jun, 23 | 30 | 3.45% |
| 31 Mar, 23 | 29 | -6.45% |
| 31 Dec, 22 | 31 | 3.33% |
| 30 Sep, 22 | 30 | -6.25% |
| 30 Jun, 22 | 32 | -8.57% |
| 31 Mar, 22 | 35 | -7.89% |
| 31 Dec, 21 | 38 | 2.70% |
| 30 Sep, 21 | 37 | -5.13% |
| 30 Jun, 21 | 39 | -22.00% |
| 31 Mar, 21 | 50 | 2.04% |
| 31 Dec, 20 | 49 | 6.52% |
| 30 Sep, 20 | 46 | 43.75% |
| 30 Jun, 20 | 32 | - |
As of 30 Jun 24, 41 institutions are holding Protara Therapeutics's shares, representing an increase of 5.13% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 10,429,817 | 128.19% |
| 31 Mar, 24 | 4,570,660 | 4.88% |
| 31 Dec, 23 | 4,358,148 | -14.85% |
| 30 Sep, 23 | 5,117,943 | -2.63% |
| 30 Jun, 23 | 5,256,367 | -4.48% |
| 31 Mar, 23 | 5,503,158 | 0.46% |
| 31 Dec, 22 | 5,478,113 | -3.19% |
| 30 Sep, 22 | 5,658,437 | -4.54% |
| 30 Jun, 22 | 5,927,633 | -8.75% |
| 31 Mar, 22 | 6,496,114 | -5.48% |
| 31 Dec, 21 | 6,872,995 | 8.88% |
| 30 Sep, 21 | 6,312,161 | -11.23% |
| 30 Jun, 21 | 7,111,082 | -16.62% |
| 31 Mar, 21 | 8,528,514 | -2.83% |
| 31 Dec, 20 | 8,776,939 | -3.68% |
| 30 Sep, 20 | 9,112,705 | 142.99% |
| 30 Jun, 20 | 3,750,178 | - |
Protara Therapeutics (TARA) has 10.43M shares outstanding as of 30 Jun 24, up 128.19% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 91.32% | 5.61% |
| 31 Mar, 24 | 40.34% | 2.73% |
| 31 Dec, 23 | 38.40% | 1.87% |
| 30 Sep, 23 | 45.26% | 2.09% |
| 30 Jun, 23 | 46.50% | 1.96% |
| 31 Mar, 23 | 48.68% | 2.06% |
| 31 Dec, 22 | 48.62% | 1.93% |
| 30 Sep, 22 | 50.23% | 1.81% |
| 30 Jun, 22 | 52.67% | 1.58% |
| 31 Mar, 22 | 57.74% | 1.54% |
| 31 Dec, 21 | 61.19% | 1.94% |
| 30 Sep, 21 | 56.18% | 1.40% |
| 30 Jun, 21 | 63.31% | 1.10% |
| 31 Mar, 21 | 75.96% | 0.52% |
| 31 Dec, 20 | 121.33% | 0.58% |
| 30 Sep, 20 | 144.09% | 3.50% |
| 30 Jun, 20 | 64.18% | - |
As of 30 Jun 24, Protara Therapeutics is held by 91.32% institutional shareholders, representing a 5.61% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 26 | 62.50% |
| 31 Mar, 24 | 16 | 77.78% |
| 31 Dec, 23 | 9 | 28.57% |
| 30 Sep, 23 | 7 | -12.50% |
| 30 Jun, 23 | 8 | 33.33% |
| 31 Mar, 23 | 6 | -25.00% |
| 31 Dec, 22 | 8 | 60.00% |
| 30 Sep, 22 | 5 | -50.00% |
| 30 Jun, 22 | 10 | -9.09% |
| 31 Mar, 22 | 11 | -45.00% |
| 31 Dec, 21 | 20 | 11.11% |
| 30 Sep, 21 | 18 | 5.88% |
| 30 Jun, 21 | 17 | -29.17% |
| 31 Mar, 21 | 24 | -11.11% |
| 31 Dec, 20 | 27 | -10.00% |
| 30 Sep, 20 | 30 | -6.25% |
| 30 Jun, 20 | 32 | - |
26 institutional shareholders have increased their position in TARA stock as of 30 Jun 24 compared to 16 in the previous quarter (a 62.50% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 7 | -22.22% |
| 31 Mar, 24 | 9 | 50.00% |
| 31 Dec, 23 | 6 | -33.33% |
| 30 Sep, 23 | 9 | 28.57% |
| 30 Jun, 23 | 7 | 16.67% |
| 31 Mar, 23 | 6 | -40.00% |
| 31 Dec, 22 | 10 | -23.08% |
| 30 Sep, 22 | 13 | - |
| 30 Jun, 22 | 13 | -23.53% |
| 31 Mar, 22 | 17 | 54.55% |
| 31 Dec, 21 | 11 | 10.00% |
| 30 Sep, 21 | 10 | -37.50% |
| 30 Jun, 21 | 16 | 60.00% |
| 31 Mar, 21 | 10 | -9.09% |
| 31 Dec, 20 | 11 | 10.00% |
| 30 Sep, 20 | 10 | - |
| 30 Jun, 20 | - | - |
7 institutional shareholders have reduced their position in TARA stock as of 30 Jun 24 compared to 9 in the previous quarter (a -22.22% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 41 | 5.13% | 10,429,817 | 128.19% | 91.32% | 5.61% | 26 | 62.50% | 7 | -22.22% |
| 31 Mar, 24 | 39 | 21.88% | 4,570,660 | 4.88% | 40.34% | 2.73% | 16 | 77.78% | 9 | 50.00% |
| 31 Dec, 23 | 32 | - | 4,358,148 | -14.85% | 38.40% | 1.87% | 9 | 28.57% | 6 | -33.33% |
| 30 Sep, 23 | 32 | 6.67% | 5,117,943 | -2.63% | 45.26% | 2.09% | 7 | -12.50% | 9 | 28.57% |
| 30 Jun, 23 | 30 | 3.45% | 5,256,367 | -4.48% | 46.50% | 1.96% | 8 | 33.33% | 7 | 16.67% |
| 31 Mar, 23 | 29 | -6.45% | 5,503,158 | 0.46% | 48.68% | 2.06% | 6 | -25.00% | 6 | -40.00% |
| 31 Dec, 22 | 31 | 3.33% | 5,478,113 | -3.19% | 48.62% | 1.93% | 8 | 60.00% | 10 | -23.08% |
| 30 Sep, 22 | 30 | -6.25% | 5,658,437 | -4.54% | 50.23% | 1.81% | 5 | -50.00% | 13 | - |
| 30 Jun, 22 | 32 | -8.57% | 5,927,633 | -8.75% | 52.67% | 1.58% | 10 | -9.09% | 13 | -23.53% |
| 31 Mar, 22 | 35 | -7.89% | 6,496,114 | -5.48% | 57.74% | 1.54% | 11 | -45.00% | 17 | 54.55% |
| 31 Dec, 21 | 38 | 2.70% | 6,872,995 | 8.88% | 61.19% | 1.94% | 20 | 11.11% | 11 | 10.00% |
| 30 Sep, 21 | 37 | -5.13% | 6,312,161 | -11.23% | 56.18% | 1.40% | 18 | 5.88% | 10 | -37.50% |
| 30 Jun, 21 | 39 | -22.00% | 7,111,082 | -16.62% | 63.31% | 1.10% | 17 | -29.17% | 16 | 60.00% |
| 31 Mar, 21 | 50 | 2.04% | 8,528,514 | -2.83% | 75.96% | 0.52% | 24 | -11.11% | 10 | -9.09% |
| 31 Dec, 20 | 49 | 6.52% | 8,776,939 | -3.68% | 121.33% | 0.58% | 27 | -10.00% | 11 | 10.00% |
| 30 Sep, 20 | 46 | 43.75% | 9,112,705 | 142.99% | 144.09% | 3.50% | 30 | -6.25% | 10 | - |
| 30 Jun, 20 | 32 | - | 3,750,178 | - | 64.18% | - | 32 | - | - | - |
Protara Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Protara Therapeutics's stock was made by Opaleye Management Inc. on Jul 18 2024, selling 7,896 shares at $2.44 per share (valued at $19.28K).
Protara Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | 10 | - |
| Q2 2024 | 8 | 18 | 44.44% |
| Q1 2024 | 10 | 10 | 100.00% |
| Q3 2023 | - | 2 | - |
| Q2 2023 | 8 | 2 | 400.00% |
| Q1 2023 | 9 | 6 | 150.00% |
| Q4 2022 | 2 | - | - |
| Q3 2022 | 6 | 9 | 66.67% |
| Q2 2022 | 20 | - | - |
| Q1 2022 | 12 | 8 | 150.00% |
| Q4 2021 | 18 | - | - |
| Q2 2021 | 12 | 1 | 1200.00% |
| Q1 2021 | 5 | 2 | 250.00% |
| Q3 2020 | 7 | 40 | 17.50% |
| Q2 2020 | 6 | - | - |
| Q1 2020 | 42 | 1 | 4200.00% |
| Q4 2019 | 3 | 3 | 100.00% |
| Q1 2019 | 9 | 3 | 300.00% |
| Q4 2018 | 4 | - | - |
| Q3 2018 | 1 | - | - |
0 total buy trades, and 10 total sell trades (buy/sell ratio of 0.00%) were made by Protara Therapeutics's insiders, as of Q3 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | 10 | - |
| Q2 2024 | - | 18 | - |
| Q1 2024 | - | - | - |
| Q3 2023 | - | - | - |
| Q2 2023 | - | - | - |
| Q1 2023 | - | - | - |
| Q4 2022 | - | 2 | - |
| Q3 2022 | 5 | - | - |
| Q2 2022 | 7 | - | - |
| Q1 2022 | 4 | - | - |
| Q4 2021 | 18 | - | - |
| Q2 2021 | 2 | - | - |
| Q1 2021 | - | - | - |
| Q3 2020 | 4 | 40 | 10.00% |
| Q2 2020 | - | - | - |
| Q1 2020 | - | - | - |
| Q4 2019 | - | - | - |
| Q1 2019 | - | - | - |
| Q4 2018 | - | - | - |
| Q3 2018 | - | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 10 open market sell trades of Protara Therapeutics's stocks.
Protara Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| SRRK | Scholar Rock Holding Corporation |
| MGTA | Dianthus Therapeutics, Inc. |
| MNPR | Monopar Therapeutics Inc. |
| MTCR | Metacrine, Inc. |
| IKNA | Ikena Oncology, Inc. |
| SRZN | Surrozen, Inc. |
| SQZ | SQZ Biotechnologies Company |
| VACC | Barinthus Biotherapeutics plc |
| VCNX | Vaccinex, Inc. |
| XLO | Xilio Therapeutics, Inc. |
| TRVI | Trevi Therapeutics, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
TARA Ownership FAQ
Who Owns Protara Therapeutics?
Protara Therapeutics is owned by institutional shareholders (91.32%), insiders (6.13%), and public (2.55%). The largest institutional shareholder of Protara Therapeutics is OPALEYE MANAGEMENT INC. (20.18% of total shares) and the top mutual fund owner is BRIDGEWAY FUNDS INC (0.02% of total shares).
Who are the major institutional shareholders of Protara Therapeutics?
Protara Therapeutics's major institutional shareholders are OPALEYE MANAGEMENT INC., RA CAPITAL MANAGEMENT, L.P., STEMPOINT CAPITAL LP, BOXER CAPITAL, LLC, and BAKER BROS. ADVISORS LP. The top five shareholders own together 57.24% of the company's share outstanding.
How many Protara Therapeutics shareholders are there?
As of Jun 2024, there are 41 institutional shareholders of Protara Therapeutics.
What percentage of Protara Therapeutics is owned by OPALEYE MANAGEMENT INC?
OPALEYE MANAGEMENT INC owns 2.3M shares of Protara Therapeutics, representing 20.18% of the company's total shares outstanding, valued at $5.3M (as of Jun 2024).
What percentage of Protara Therapeutics is owned by RA CAPITAL MANAGEMENT, L.P?
As of Jun 2024, RA CAPITAL MANAGEMENT, L.P holds 1.9M shares of Protara Therapeutics (TARA), compromising 16.64% of the company, valued at $3.95M.
What percentage of Protara Therapeutics is owned by STEMPOINT CAPITAL LP?
STEMPOINT CAPITAL LP is the third largest holder of Protara Therapeutics. The company owns 984.11K of the company's shares outstanding (worth $2.05M).